Professor of Ocular Angiogenesis in the Faculty of Medicine (University of Amsterdam) and Head of the Ocular Angiogenesis Group (University of Amsterdam Academic Medical Centre), The Netherlands
Dr. Reinier O. Schlingemann is among the foremost researchers in ocular angiogenesis and anti-VEGF therapy in the eye. After receiving his medical degree from the University of Leiden Medical School, the Netherlands, Dr. Schlingemann gained his PhD from the University of Nijmegen in 1990, on the subjects of tumor angiogenesis and tumor vascular targeting. He undertook his residency in ophthalmology at the University of Amsterdam, followed by a medical retina fellowship with Professor Alan Bird at Moorfields Eye Hospital, London. He is now Professor of Ophthalmology and a medical retinal specialist in Amsterdam.
Dr. Schlingemann’s research interests include the role of growth factors in ocular angiogenesis and fibrosis (particularly in AMD and diabetic retinopathy); the cellular mechanisms underlying loss of the blood–retinal barrier in diabetic retinopathy; and vaso-occlusive mechanisms that cause non-perfusion of the retinal vasculature in diabetic retinopathy. He is also involved in several prospective clinical trials on the use of anti-angiogenic therapy in AMD and diabetic retinopathy.